Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma.
Inamoto T, Sato R, Matsushita Y, Uchimoto T, Nakamura KO, Komura K, Nishimura K, Yano Y, Nishio K, Kinoshita S, Fukushima T, Matsunaga T, Nakamori K, Tsutsumi T, Tsujino T, Uehara H, Takahara K, Miyake H, Azuma H.
Inamoto T, et al. Among authors: miyake h.
Cancer Diagn Progn. 2023 May 3;3(3):370-376. doi: 10.21873/cdp.10226. eCollection 2023 May-Jun.
Cancer Diagn Progn. 2023.
PMID: 37168961
Free PMC article.